Who are ILUMYA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Omvoh, Skyrizi, Sunpg 1622, TILD, OMVOH, Stelara.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tildrakizumab-asmn.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ILUMYA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ILUMYA (TILDRAKIZUMAB-ASMN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-23 Antagonist [EPC]. Area: Immunology.

marketed Interleukin-23 Antagonist [EPC] Interleukin-23 Immunology Live · refreshed every 30 min

Target snapshot

ILUMYA (TILDRAKIZUMAB-ASMN) — SUN PHARMA GLOBAL.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ILUMYA TARGET	TILDRAKIZUMAB-ASMN	SUN PHARMA GLOBAL	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23
Omvoh	MIRIKIZUMAB	Eli Lilly Nederland B.V.	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2023-01-01
Skyrizi	RISANKIZUMAB	AbbVie	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2019-01-01
Sunpg 1622	TILDRAKIZUMAB	Sun Pharma Global	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23	2018-01-01
TILD	TILD	Sun Pharmaceutical Industries Limited	marketed		Interleukin-23
OMVOH	MIRIKIZUMAB-MRKZ	ELI LILLY AND CO	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha
Stelara	Stelara	Biocon Biologics UK Ltd	marketed		Interleukin-12, Interleukin-23

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-23 Antagonist [EPC] class)

AbbVie · 1 drug in this class
ELI LILLY AND CO · 1 drug in this class
Eli Lilly Nederland B.V. · 1 drug in this class
Johnson & Johnson · 1 drug in this class
SUN PHARMA GLOBAL · 1 drug in this class
Sun Pharma Global · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ILUMYA — Competitive Intelligence Brief. https://druglandscape.com/ci/tildrakizumab-asmn. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing